Eli Lilly (LLY) EVP & CIDO Diogo Rau receives 4,432-share stock grant

Rhea-AI Filing Summary

Eli Lilly executive Diogo Rau reported an equity award in company stock. On 02/09/2026, the EVP & CIDO acquired 4,432.32 shares of Eli Lilly common stock through a grant or award at a price of $1,044.67 per share. Following this transaction, Rau directly beneficially owned 26,229.69 shares of Eli Lilly common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rau Diogo

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS IN 46285

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CIDO

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		4,432.32	A	$1,044.67	26,229.69	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Jonathan Groff for Diogo Rau, pursuant to authorization on file	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Eli Lilly (LLY) report for Diogo Rau?

Eli Lilly reported that EVP & CIDO Diogo Rau received a grant of 4,432.32 common shares on February 9, 2026. This was recorded as a grant or award acquisition rather than an open-market purchase or sale.

At what price was Diogo Rau’s Eli Lilly (LLY) stock grant recorded?

The grant to Diogo Rau was recorded at $1,044.67 per share for Eli Lilly common stock. This figure reflects the transaction price used for reporting the equity award on the Form 4 insider transaction filing.

How many Eli Lilly (LLY) shares does Diogo Rau own after this grant?

After the reported grant, Diogo Rau beneficially owned 26,229.69 shares of Eli Lilly common stock directly. This total includes the newly acquired 4,432.32 shares reported in the February 9, 2026 Form 4 filing.

What role does Diogo Rau hold at Eli Lilly (LLY) in this Form 4 filing?

In the Form 4, Diogo Rau is identified as an officer of Eli Lilly with the title EVP & CIDO. This indicates he is an executive vice president and chief information and digital officer of the company.

Was Diogo Rau’s Eli Lilly (LLY) transaction a purchase or an award?

The transaction is classified as a grant, award, or other acquisition under code A, not an open-market buy. It reflects equity-based compensation, with 4,432.32 common shares credited to Diogo Rau on February 9, 2026.

Is Diogo Rau’s ownership in Eli Lilly (LLY) direct or indirect after the transaction?

Following the reported transaction, the 26,229.69 Eli Lilly shares are shown as directly owned by Diogo Rau. The Form 4 lists the ownership form as “D” for direct, with no indirect ownership nature specified in the filing.